Michael Davis becomes Cyanotech chairman

Hawaiian microalgae technology company looks forward to continuing support of its major shareholder

Michael Davis has been elected as chairman of Hawaii-based Cyanotech Corporation. He replaces Gregg Robertson, who resigned in late 2010.

Davis was vice-chairman of the board and has been a director of Cyanotech since March 2003.

‘Michael has been a key influence in helping Cyanotech sharpen its business model and market focus in recent years,’ said Brent Bailey, president and ceo. ‘We look forward to his continuing support and leadership as chairman of the board.’

Cyanotech Corporation, a microalgae technology specialist, produces BioAstin Natural Astaxanthin and Hawaiian Spirulina Pacifica, which are natural, functional nutrients.

You may also like

Ingredients

De-risk early stage drug development with Lonza Advanced Synthesis

Located at stand 5.1B76, Lonza is set to shed light on the issues facing drug developers and how AI-assisted tools improve the process
Ingredients

Roquette launches KLEPTOSE Crysmeb methyl-beta-cyclodextrin for oral and parenteral formulations

The addition of the novel pharmaceutical excipient boosts the company's already extensive cyclodextrins portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals

People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS
Ingredients

CPHI 2025: BENEO to present galenIQ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October), BENEO will showcase the latest advancements in granulation with its pharmaceutical-grade isomalt excipient: galenIQ
Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Subscribe now